Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lilly

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

MarketBeat

These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth

Netflix is among the stocks with most bullish analyst ratings. (Netflix)

Investors Business Daily

Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch

Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Hims Stock Jumps After Adding Eli Lilly's Obesity Drug To Its Platform

Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform.

Investors Business Daily

Experimental Drug Shows Promise In Eliminating Hard-To-Treat Deadly Cholesterol

A single dose of lepodisiran dramatically lowered dangerous lipoprotein(a) levels for up to a year, offering new hope for heart disease treatment.

Medical Daily

European committee says Lilly Alzheimer's drug shouldn't get marketing approval

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling

The Independent UK

Price Targets Show These 3 Stocks Near the $1 Trillion Mark

See what analysts' price targets say about the prospects of these three stocks flirting with the $1 trillion valuation mark.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk Finds A New Way To Rival Eli Lilly. But Shares Tumble.

Novo Nordisk stock dropped Monday after the drugmaker licensed a Chinese competitor's weight-loss drug for $200 million up front.

Investors Business Daily

Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?

Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.

MarketBeat

Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors

Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.

MarketBeat

Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors

Pharma giant Eli Lilly announced plans to make a massive investment in the United States. What does this and another big announcement mean for Lilly?

MarketBeat

Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside

Novo Nordisk shares are closing in on a new 52-week low. Is the stock gearing up for a recovery with sentiment currently low?

MarketBeat

Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial

Eli Lilly is still seeing rapid sales growth for its diabetes and weight loss drugs. However, one drug waiting in the wings hopes to be its next blockbuster.

MarketBeat

Meet the 24-year-old helping Lilly test a preventive Alzheimer’s drug

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same age their parents did.

Fortune

Get all your
news in one place.

100’s of premium titles.
One news app.

Kiplinger

Eli Lilly Stock Rises After Profit, Outlook Top Expectations

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 guidance. Here's what you need to know.

The Independent UK

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast

Investors Business Daily

Eli Lilly Jumps, Reversing Its Weight-Loss Setback, On A Strong 2025 Outlook

Eli Lilly stock rose Thursday despite lighter-than-expected sales of its weight-loss and diabetes drugs Zepbound and Mounjaro.

Fortune

Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug your doctor prescribed.

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Apple, Nvidia, and more of the 2025 World's Most Admired Companies

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

MarketBeat

What Does the Future Hold for Eli Lilly?

Eli Lilly's two major GLP-1 drugs have dominated headlines, but a slate of new treatments in development—and some already available—suggest a bright future.

Investors Business Daily

Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms

Novo Nordisk stock surged Friday after the obesity kingpin reported strong results for its next-generation weight-loss drug, amycretin.

The Independent UK

The Misty Isle’s magic: Feasting my way around the Isle of Skye

TOP TABLES: What happens when a food writer swaps London’s bustle for Scotland’s beauty? Lilly Subbotin discovers the unexpected culinary delights of Skye – from langoustines on a harbour boat to black garlic butter that tastes like witchcraft

Investors Business Daily

Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review

The stock market rebounded to or above key levels on tame inflation data and strong bank earnings. Many stocks flashed buy signals.

Investors Business Daily

After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

The Conversation

How we diagnose and define obesity is set to change – here’s why, and what it means for treatment

Obesity is linked to many common diseases, such as type 2 diabetes, heart disease, fatty liver disease and knee osteoarthritis.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.